Tikva Allocell Selected to Present Preclinical CD19.SB9.CAR-EBVST Data at ACR Convergence 2026
Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosus SINGAPORE, Oct. 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd. ("Tikva"), a biotechnology...
Covered in this story
Call it yourself
No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Acres Commercial Realty Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.